About this Journal Submit a Manuscript Table of Contents
Journal of Oncology
Volume 2009 (2009), Article ID 408038, 8 pages
http://dx.doi.org/10.1155/2009/408038
Research Article

Synergistic Induction of Apoptosis in Primary B-CLL Cells after Treatment with Recombinant Tumor Necrosis Factor-Related Apoptosis-Inducing Ligand and Histone Deacetylase Inhibitors

Department of Urology and Interdisciplinary Graduate Program in Immunology, University of Iowa Carver College of Medicine, Iowa City, IA 52242, USA

Received 8 September 2008; Revised 6 February 2009; Accepted 10 April 2009

Academic Editor: Michael A. Carducci

Copyright © 2009 Lyse A. Norian et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Citations to this Article [8 citations]

The following is the list of published articles that have cited the current article.

  • Ugo Testa, “TRAIL/TRAIL-R in Hematologic Malignancies,” Journal of Cellular Biochemistry, vol. 110, no. 1, pp. 21–34, 2010. View at Publisher · View at Google Scholar
  • Giorgio Zauli, Raffaella Bosco, and Paola Secchiero, “Molecular targets for selective killing of TRAIL-resistant leukemic cells,” Expert Opinion on Therapeutic Targets, vol. 15, no. 8, pp. 931–942, 2011. View at Publisher · View at Google Scholar
  • Richard Lemal, Aurelie Ravinet, Cecile Molucon-Chabrot, Jacques-Olivier Bay, and Romain Guieze, “Histone deacetylase inhibitors in the treatment of hematological malignanci es,” Bulletin Du Cancer, vol. 98, no. 8, pp. 867–878, 2011. View at Publisher · View at Google Scholar
  • Gabrielle M. Siegers, Helena Dhamko, Xing-Hua Wang, A. Mark Mathieson, Yoko Kosaka, Tania C. Felizardo, Jeffrey A. Medin, Shuji Tohda, Julia Schueler, Paul Fisch, and Armand Keating, “Human V delta 1 gamma delta T cells expanded from peripheral blood exhibit specific cytotoxicity against B-cell chronic lymphocytic leukemia-derived c ells,” Cytotherapy, vol. 13, no. 6, pp. 753–764, 2011. View at Publisher · View at Google Scholar
  • Lyse A. Norian, Britnie R. James, and Thomas S. Griffith, “Advances in viral vector-based TRAIL gene therapy for cancer,” Cancers, vol. 3, no. 1, pp. 603–620, 2011. View at Publisher · View at Google Scholar
  • Juergen Sonnemann, Navina Trommer, Sabine Becker, Susan Wittig, Desiree Grauel, Chithra D. Palani, and James F. Beck, “Histone deacetylase inhibitor-mediated sensitization to TRAIL-induced apopt osis in childhood malignancies is not associated with upregulation of TRAIL receptor expression, but with potentiated caspase-8 activation,” Cancer Biology & Therapy, vol. 13, no. 6, pp. 417–424, 2012. View at Publisher · View at Google Scholar
  • Jürgen Sonnemann, Navina Trommer, Sabine Becker, Susan Wittig, Désirée Grauel, Chithra D. Palani, and James F. Beck, “Histone deacetylase inhibitor-mediated sensitization to TRAIL-induced apoptosis in childhood malignancies is not associated with upregulation of TRAIL receptor expression, but with potentiated caspase-8 activation,” Cancer Biology & Therapy, vol. 13, no. 6, pp. 417–424, 2012. View at Publisher · View at Google Scholar
  • Graham R. Leggatt, and Brian Gabrielli, “Histone deacetylase inhibitors in the generation of the anti-tumour immune response,” Immunology and Cell Biology, vol. 90, no. 1, pp. 33–38, 2012. View at Publisher · View at Google Scholar